Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
DINUCLEOTIDE COMPOUNDS FOR TREATING CANCERS AND MEDICAL USES THEREOF
Document Type and Number:
WIPO Patent Application WO/2021/020879
Kind Code:
A1
Abstract:
The present disclosure provides the dinucleotide compounds which is useful for treating various cancers. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating cancer. The present disclosure also provides a method of treatment of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment.

Inventors:
JUNG DOO-YOUNG (KR)
LEE JIN-SOO (KR)
CHO HYUN-YONG (KR)
KIM YE-JI (KR)
Application Number:
PCT/KR2020/010006
Publication Date:
February 04, 2021
Filing Date:
July 29, 2020
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
PINOTBIO INC (KR)
International Classes:
C07H19/24; A61K31/7042; A61P35/00; C07H1/00; C07H19/073
Domestic Patent References:
WO1997011087A11997-03-27
Foreign References:
US20100151001A12010-06-17
Other References:
SUGIYAMA, H. et al., "Specific detection of C-4`hydroxylated abasic sites generated by bleomycin and neocarzinostatin in DNA", J. am. chem. soc., 1990, Vol. 112, No. 13, pp. 5252-5257 abstract; scheme II
SCHOTT, H. ; SCHOTT, S. ; SCHWENDENER, R.A.: "Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER, NL, vol. 17, no. 19, 1 October 2009 (2009-10-01), NL, pages 6824 - 6831, XP026601529, ISSN: 0968-0896, DOI: 10.1016/j.bmc.2009.08.033
STRASSER, S. ; MAIER, S. ; LEISSER, C. ; SAIKO, P. ; MADLENER, S. ; BADER, Y. ; BERNHAUS, A. ; GUEORGUIEVA, M. ; RICHTER, S. ; MAD: "5-FdUrd-araC heterodinucleoside re-establishes sensitivity in 5-FdUrd- and AraC-resistant MCF-7 breast cancer cells overexpressing ErbB2", DIFFERENTIATION., SPRINGER VERLAG., DE, vol. 74, no. 9-10, 1 December 2006 (2006-12-01), DE, pages 488 - 498, XP026770200, ISSN: 0301-4681, DOI: 10.1111/j.1432-0436.2006.00082.x
Attorney, Agent or Firm:
PHIL & ONZI INT'L PATENT & LAW FIRM (KR)
Download PDF: